Ensysce Biosciences, Inc. (ENSC) - Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. Ensysce Biosciences, Inc. is a clinical-stage biotechnology company focused on developing abuse-resistant and overdose-protective opioid therapies. The company's lead product candidate, PF614 (an extended-release TAAP prodrug of oxycodone), is in Phase 3 clinical development, while PF614-MPAR is in Phase 1b. The company has no approved products and has not generated revenue from product sales.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue (Federal Grants) | $1,319,772 | $305,722 |
| Net Loss | $(1,945,573) | $(3,116,563) |
| Net Loss Per Share (Basic/Diluted) | $(1.39) | $(8.21) |
| Cash and Cash Equivalents (End of Period) | $3,052,491 | $3,404,349 |
| Total Debt (Notes Payable & Accrued Interest) | $257,383 | $301,660 |
| Net Cash Used in Operating Activities | $(1,707,412) | $(3,408,403) |
| Net Cash Provided by Financing Activities | $1,257,826 | $5,689,148 |
Material Changes vs. Prior Period
- Revenue Increase: Federal grant revenue increased by approximately $1.0 million ($1.3M vs. $0.3M), driven by increased activity under the new MPAR Grant awarded in August 2024.
- Reduced Net Loss: Net loss decreased by $1.17 million compared to Q1 2024. This improvement was primarily due to a significant reduction in interest expense (from $1.25M to $3.9K) as the amortization of debt discounts and issuance costs for the 2023 Notes was completed in 2024.
- Operating Expenses: Total operating expenses increased by $1.14 million to $3.29 million. Research and Development (R&D) expenses rose by $1.11 million to $1.89 million due to increased external costs for clinical and pre-clinical programs. General and Administrative (G&A) expenses remained relatively flat at $1.40 million.
- Capital Raise: In March 2025, the company completed a registered direct offering and warrant offering, generating gross proceeds of approximately $1.1 million.
Guidance, Outlook, and Risks
- Going Concern: The filing explicitly states that the company's ability to continue as a going concern for the next 12 months is in substantial doubt. Management estimates current cash resources are sufficient to fund operations only into the third quarter of 2025 without additional financing.
- Liquidity: The company relies on federal grants (with $9.2 million remaining under the MPAR Grant through May 2027) and equity/debt financings. It has no product revenue.
- Commitments: As of March 31, 2025, the company has approximately $7.9 million in open purchase orders and contractual obligations, primarily for clinical research studies.
- Risks: Key risks include the failure of clinical trials for PF614 and PF614-MPAR, inability to secure additional funding, potential delisting from Nasdaq, and reliance on third-party CROs and CMOs.
- Subsequent Events: In April 2025, the company entered into agreements to exercise March 2025 warrants, generating an additional $2.2 million in gross proceeds.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the Q3 2025 liquidity horizon.
- Grant Utilization: Confirm the status of the $9.2 million remaining NIH/NIDA MPAR Grant funding and any conditions attached to its drawdown.
- Debt Obligations: Review the terms of the remaining $216,000 principal balance on the 2023 Notes held by a board member and the associated forbearance agreement expiring April 2026.
- Dilution: Assess the impact of the 2.77 million outstanding warrants and the recent April 2025 warrant exercises on future share count.
- Clinical Milestones: Monitor progress on the Phase 3 trial for PF614 and Phase 1b for PF614-MPAR, as these are critical for future valuation and funding.